To the research team working to save him, KJ Muldoon was first known only as Patient Eta. But within months, KJ’s name — and ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing novel immunotherapies and vaccines for solid tumor cancers and infectious diseases, today announced the publication ...

In return, Royalty will receive a 9.25% royalty on worldwide sales of tividenofusp alfa from Denali until it reaches three times the amount Royalty has handed to Denali—or, alternatively, 2.5 times ...

The FDA has placed a hold on Denali Therapeutics’ plans to launch a phase 1 rare disease trial, citing concerns about immune ...

Hypersensitivity reactions in a mouse model prompted the agency to suspend Denali’s planned Phase I development for DNL952 ...

Patna: Once dismissed as a relic of medieval medicine, leech therapy is crawling back into Bihar’s healing scene. What was ...

Lynk received the green light from the FDA to begin clinical trials of its investigational oral therapy LNK01006 for MS and other diseases.

Cell death triggered by GPX4 loss was slowed in cell cultures and in mouse model using compounds that specifically inhibit ferroptosis.

Pirtobrutinib, a non-covalent Bruton tyrosine kinase (BTK) inhibitor, met the primary endpoint for non-inferiority in terms of overall response rate in the first head-to-head comparison with ibrutinib ...

Neflamapimod is an oral p38 alpha kinase inhibitor that targets dysfunction and degeneration of acetylcholine-producing ...

Why do nerve cells die in dementia - and can this process be slowed down? Researchers from the Technical University of Munich ...

Mirum inks 620M deal to acquire Bluejay Therapeutics, adding brelovitug, a phase 3 hepatitis delta drug, to its liver disease pipeline.